Trinity Announces Creation of Forty New Academic Posts

Posted on: 27 March 2015

Forty new academic posts are being created across Trinity College Dublin to support the delivery of the College’s new Strategic Plan 2014-19.

Commenting on the significance of these new posts, the Vice-Provost/Chief Academic Officer, Professor Linda Hogan stated: “I am delighted to announce the creation of 40 ‘new blood’ Ussher Assistant Professorships which are designed to build academic capacity to deliver the College’s Strategic Plan. They will enable Schools (working with the Library where that would be an advantage) to develop new activities or strengthen existing ones by recruiting academics of the highest-calibre to tenure-track positions.”

These new posts are being funded entirely by non-exchequer sources through Trinity’s Commercial Revenue Unit.  Funding will be provided for up to five years for an Assistant Professor appointed on a tenure-track, to be mainstreamed after a 5-year period subject to performance. Recruitment will be at entry-level, targeting currently high performers with strong research profiles.

The call for proposals for this new round of Ussher Assistant Professorships is now open. The strongest proposals will be those that develop the university through increasing the capacity to perform excellent research of impact (whether disciplinary or interdisciplinary); enhancing the Schools’ capacity to deliver online and technology-enhanced education; fostering global engagement in education and research; and contributing to the delivery of the Innovation & Entrepreneurship Strategy. Schools are invited to submit their proposals by Friday 24 April 2015. All proposals must be submitted through Heads of School.

This current round of Ussher Assistant Professorships follows a similar initiative in 2010 when 40 Ussher Assistant Professors were recruited internationally, across a wide range of areas such as 18th Century French Studies, Entrepreneurship and Innovation, Nanomagnetism, Virology, Cancer Biology and Therapeutics, and Molecular Oncology.